|
1
|
Dibble EH, Alvarez AC, Truong MT, Mercier
G, Cook EF and Subramaniam RM: 18F-FDG metabolic tumor volume and
total glycolytic activity of oral cavity and oropharyngeal squamous
cell cancer: adding value to clinical staging. J Nucl Med.
53:709–715. 2012.
|
|
2
|
Kaira K, Okumura T, Ohde Y, et al:
Correlation between 18F-FDG uptake on PET and molecular biology in
metastatic pulmonary tumors. J Nucl Med. 52:705–711. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao K, Luo XM, Zhou SH, et al:
(18)F-Fluorodeoxyglucose positron emission
tomography/computed tomography as an effective diagnostic workup in
cervical metastasis of carcinoma from an unknown primary tumor.
Cancer Biother Radiopharm. 27:685–693. 2012. View Article : Google Scholar
|
|
4
|
Hentschel M, Paulus T, Mix M, Moser E,
Nitzsche EU and Brink I: Analysis of blood flow and glucose
metabolism in mammary carcinomas and normal breast: a H2(15)O PET
and 18F-FDG PET study. Nucl Med Commun. 28:789–797. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
6
|
Zhou S, Wang S, Wu Q, Fan J and Wang Q:
Expression of glucose transporter-1 and -3 in the head and neck
carcinoma - the correlation of the expression with the biological
behaviors. ORL J Otorhinolaryngol Relat Spec. 70:189–194. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esen Akkas B, Gökaslan D, Güner L and
Ilgin Karabacak N: FDG uptake in brown adipose tissue-a brief
report on brown fat with FDG uptake mechanisms and quantitative
analysis using dual-time-point FDG PET/CT. Rev Esp Med Nucl.
30:14–18. 2001.
|
|
8
|
Prante O, Maschauer S, Fremont V, et al:
Regulation of uptake of 18F-FDG by a follicular human thyroid
cancer cell line with mutation-activated K-ras. J Nucl Med.
50:1364–1370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han MW, Lee HJ, Cho KJ, et al: Role of
FDG-PET as a biological marker for predicting the hypoxic status of
tongue cancer. Head Neck. 34:1395–1402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li XF, Ma Y, Sun X, Humm JL, Ling CC and
O’Donoghue JA: High 18F-FDG uptake in microscopic peritoneal tumors
requires physiologic hypoxia. J Nucl Med. 51:632–638. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alakus H, Batur M, Schmidt M, et al:
Variable 18F-fluorodeoxyglucose uptake in gastric cancer is
associated with different levels of GLUT-1 expression. Nucl Med
Commun. 31:532–538. 2010.PubMed/NCBI
|
|
12
|
Nagamatsu A, Umesaki N, Li L and Tanaka T:
Use of 18F-fluorodeoxyglucose positron emission tomography for
diagnosis of uterine sarcomas. Oncol Rep. 23:1069–1076.
2010.PubMed/NCBI
|
|
13
|
Luo XM, Zhou SH and Fan J: Glucose
transporter-1 as a new therapeutic target in laryngeal carcinoma. J
Int Med Res. 38:1885–1892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rademakers SE, Lok J, van der Kogel AJ,
Bussink J and Kaanders JH: Metabolic markers in relation to
hypoxia; staining patterns and colocalization of pimonidazole,
HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer.
11:1672011.PubMed/NCBI
|
|
15
|
Kaira K, Serizawa M, Koh Y, et al:
Relationship between 18F-FDG uptake on positron emission tomography
and molecular biology in malignant pleural mesothelioma. Eur J
Cancer. 48:1244–1254. 2012. View Article : Google Scholar
|
|
16
|
Izuishi K, Yamamoto Y, Sano T, et al:
Molecular mechanism underlying the detection of colorectal cancer
by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography. J
Gastrointest Surg. 16:394–400. 2012. View Article : Google Scholar
|
|
17
|
Robey IF, Stephen RM, Brown KS, Baggett
BK, Gatenby RA and Gillies RJ: Regulation of the Warburg effect in
early-passage breast cancer cells. Neoplasia. 10:745–756. 2008.
|
|
18
|
Bos R, van Der Hoeven JJ, van Der Wall E,
et al: Biologic correlates of (18)fluorodeoxyglucose uptake in
human breast cancer measured by positron emission tomography. J
Clin Oncol. 20:379–387. 2002. View Article : Google Scholar
|
|
19
|
Machtay M, Natwa M, Andrel J, et al:
Pretreatment FDG-PET standardized uptake value as a prognostic
factor for outcome in head and neck cancer. Head Neck. 31:195–201.
2009. View Article : Google Scholar
|
|
20
|
Li LF, Zhou SH, Zhao K, et al: Clinical
significance of FDG single-photon emission computed tomography:
Computed tomography in the diagnosis of head and neck cancers and
study of its mechanism. Cancer Biother Radiopharm. 23:701–714.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zimny M, Gagel B, DiMartino E, et al: FDG
- a marker of tumour hypoxia? A comparison with
[18F]fluoromisonidazole and pO2-polarography in metastatic head and
neck cancer. Eur J Nucl Med Mol Imaging. 33:1426–1431. 2006.
|
|
22
|
Gagel B, Piroth M, Pinkawa M, et al: pO
polarography, contrast enhanced color duplex sonography (CDS),
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron
emission tomography: validated methods for the evaluation of
therapy-relevant tumor oxygenation or only bricks in the puzzle of
tumor hypoxia? BMC Cancer. 7:1132007.PubMed/NCBI
|
|
23
|
Shen WQ, Cheng KJ, Bao YY, Zhou SH and Yao
HT: Expression of Glut-1, HIF-1α, PI3K and p-Akt in a case of
ceruminous adenoma. Head Neck Oncol. 4:182012.
|
|
24
|
Shafee N, Kaluz S, Ru N and Stanbridge EJ:
PI3K/Akt activity has variable cell-specific effects on expression
of HIF target genes, CA9 and VEGF, in human cancer cell lines.
Cancer Lett. 282:109–115. 2009. View Article : Google Scholar
|
|
25
|
Morani F, Pagano L, Prodam F, Aimaretti G
and Isidoro C: Loss of expression of the oncosuppressor PTEN in
thyroid incidentalomas associates with GLUT1 plasmamembrane
expression. Panminerva Med. 54:59–63. 2012.
|
|
26
|
Fang J, Luo XM, Yao HT, Zhou SH, Ruan LX
and Yan SX: Expression of glucose transporter-1, hypoxia-inducible
factor-1α, phosphatidylinositol 3-kinase and protein kinase B (Akt)
in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal
diffuse large B-cell lymphoma: a case report and literature review.
J Int Med Res. 38:2160–2168. 2010.
|
|
27
|
Bae JS, Roh JL, Lee SW, et al: Laryngeal
edema after radiotherapy in patients with squamous cell carcinomas
of the larynx and hypopharynx. Oral Oncol. 48:853–858. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haerle SK, Schmid DT, Ahmad N, Hany TF and
Stoeckli SJ: The value of (18)F-FDG PET/CT for the detection of
distant metastases in high-risk patients with head and neck
squamous cell carcinoma. Oral Oncol. 47:653–659. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schinagl DA, Span PN, Oyen WJ and Kaanders
JH: Can FDG PET predict radiation treatment outcome in head and
neck cancer? Results of a prospective study. Eur J Nucl Med Mol
Imaging. 38:1449–1458. 2011. View Article : Google Scholar
|
|
30
|
Tian M, Zhang H, Nakasone Y, Mogi K and
Endo K: Expression of Glut-1 and Glut-3 in untreated oral squamous
cell carcinoma compared with FDG accumulation in a PET study. Eur J
Nucl Med Mol Imaging. 31:5–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang J, Bao YY, Zhou SH, et al: Recurrent
prognostic factors and expression of GLUT-1, PI3K and p-Akt in
adenoid cystic carcinomas of the head and neck: Clinicopathological
features and biomarkers of adenoid cystic carcinoma. Oncol Lett.
4:1234–1240. 2012.PubMed/NCBI
|
|
32
|
Melstrom LG, Salabat MR, Ding XZ, et al:
Apigenin inhibits the GLUT-1 glucose transporter and the
phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer
cells. Pancreas. 37:426–431. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ahn KJ, Hwang HS, Park JH, et al:
Evaluation of the role of hexokinase type II in cellular
proliferation and apoptosis using human hepatocellular carcinoma
cell lines. J Nucl Med. 50:1525–1532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burrows N, Babur M, Resch J, et al:
GDC-0941 inhibits metastatic characteristics of thyroid carcinomas
by targeting both the phosphoinositide-3 kinase (PI3K) and
hypoxia-inducible factor-1α (HIF-1α) pathways. J Clin Endocrinol
Metab. 96:E1934–E1943. 2011.PubMed/NCBI
|
